Category: md anderson

Court dismisses biochemist’s lawsuit against MD Anderson

Credit: 12963734/iStock

A Texas court has dismissed a lawsuit by a biochemist accused of research misconduct who claimed her former institution violated her due process rights during its investigation. 

Sonia Melo sued The University of Texas MD Anderson Cancer Center in Houston in 2025, alleging the institution failed to follow its policies during a misconduct investigation into her work. MD Anderson found in May 2024 Melo had engaged in research misconduct while a postdoctoral fellow between 2012 and 2014, according to court documents.

Attorneys for MD Anderson requested a judge dismiss the suit in February, arguing the institution is a governmental entity entitled to sovereign immunity that protects it from lawsuits seeking money. Under Texas law, public hospitals are shielded from most suits by immunity rules. Some loopholes for medical negligence exist, such as when medical equipment harms patients. 

Continue reading Court dismisses biochemist’s lawsuit against MD Anderson

Cancer researcher has correction upgraded to retraction

mol endo coverRakesh Kumar, a researcher with six recent corrections and one retraction, has had one of those corrections upgraded to a retraction.

Here’s the unhelpful notice, from Molecular Endocrinology: Continue reading Cancer researcher has correction upgraded to retraction

IRB mishap costs MD Anderson team a paper on prostate cancer

bjuifeb14A group of researchers from MD Anderson Cancer Center in Houston has lost a 2013 paper in BJU International for running afoul of their institution’s ethics review board, and of military reviewers, as well.

The paper, “Many young men with prostate-specific antigen (PSA) screen-detected prostate cancers may be candidates for active surveillance,” looked at prostate cancer screening in men 55 and under — considered young for the older-man’s disease. According to the abstract: Continue reading IRB mishap costs MD Anderson team a paper on prostate cancer

Two Expressions of Concern in Blood for MD Anderson’s Aggarwal, who has threatened to sue Retraction Watch

aggarwalBharat Aggarwal, the MD Anderson researcher who has threatened to sue us while under investigation by his institution for alleged misconduct, now has two Expressions of Concern in addition to two corrections and two unexplained withdrawals.

Both of the papers were published in Blood. The Expression of Concern for “Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-κB signaling pathway,” reads: Continue reading Two Expressions of Concern in Blood for MD Anderson’s Aggarwal, who has threatened to sue Retraction Watch

Scientist whose work is “not fully supported by the available laboratory records” to retract 8 more papers

SK Manna
SK Manna

Yesterday, we reported that Sunil Kumar Manna, the head of immunology at India’s Centre for DNA Fingerprinting and Diagnostics, had retracted two papers for image problems.

Turns out Manna will be retracting eight more, he told us today. Here they are: Continue reading Scientist whose work is “not fully supported by the available laboratory records” to retract 8 more papers

Correction for MD Anderson’s Bharat Aggarwal arches eyebrows for the right reasons

We’ve written about mega-corrections that allow scientists to retrace virtually all of their steps yet preserve their publications as supposedly legitimate. And we’ve seen plenty of corrections that allow authors to assert that their conclusions are correct when evidently important pieces of data are themselves unreliable.

Now comes a correction that seems to us to strike the right chords, given the fact that editors are to a large extent at the mercy of authors in these situations. Continue reading Correction for MD Anderson’s Bharat Aggarwal arches eyebrows for the right reasons

Another withdrawal by MD Anderson’s Aggarwal, again for unclear reasons

Bharat B. Aggarwal, the MD Anderson researcher under investigation at his institution over concerns of image manipulation, has withdrawn a second paper, although you’d never know why from the statement.

The notice for the article, “Evidence for the critical roles of NF-κB p65 and specificity proteins in the apoptosis-inducing activity of proteasome inhibitors in leukemia cells,” is pretty minimal: Continue reading Another withdrawal by MD Anderson’s Aggarwal, again for unclear reasons